
Quiz|Articles|June 19, 2026
OncLive Weekly News Quiz (6/19/2026): Did You Catch This Week's Updates in LBCL and Breast Cancer?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
What key regulatory development was reported for subcutaneous mosunetuzumab plus polatuzumab vedotin?
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer
2
Neoadjuvant Nivolumab Plus Ipilimumab Yields High PFS, OS Rates in Locally Advanced Cervical Cancer
3
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer
4
FDA Accepts sBLA for Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL
5








































































